Here are the latest stories being discussed in biopharma today:

FDA Approves Vertex and CRISPR’s First CRISPR-Edited Therapy for Beta-Thalassemia

The Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy for the treatment of beta-thalassemia, marking it the first-ever CRISPR-edited therapy for this rare genetic blood disorder. The one-time ex vivo treatment is priced at $2.2 million and is approved for patients aged 12 years and older who need regular blood transfusions to survive.

Pharma Giants Utilizing Tech for Future Strategies

Pharma giants, including GSK and Bristol Myers, are increasingly getting creative with tech-based ideas to overhaul areas outside of R&D. Through collaborations with companies like Nvidia, they are using technology in their drug discovery and clinical trials to shave off time.

Fair Price Deadline Approaches for the Inflation Reduction Act

With a key February deadline approaching, amicus briefs are piling up in support of drug price negotiations under the Inflation Reduction Act. Potential outcomes could impact the affordability of prescription drugs, the financial stability of Medicare, and taxpayers.

Novo Nordisk Resumes Advertising for Obesity Drug Wegovy

Novo Nordisk is relaunching its advertising for the obesity drug, Wegovy, with a new campaign labeled “Believe On.” The campaign aims to create an emotional connection with consumers, focusing on the realistic ups and downs of obesity and chronic weight management.

Oncology Drugs Lead 2023 New Medicines in Europe – EMA Report

The European Medicines Agency (EMA) approved 77 new drugs in 2023, with oncology medications leading the number of positive opinions. This is a boost for patients with cancer, a disease that affects millions of people every year.

Merck Receives Third Cervical Cancer Approval for Keytruda

Merck’s blockbuster drug, Keytruda, has secured its third US approval for cervical cancer. Keytruda is now the only anti-PD-1 therapy approved for use in combination with chemoradiation therapy for patients with advanced cervical cancer. This approval continues Keytruda’s multiple success streak across a range of indications.